CN109475629A - 用notch和pd-1或pd-l1抑制剂的组合治疗 - Google Patents

用notch和pd-1或pd-l1抑制剂的组合治疗 Download PDF

Info

Publication number
CN109475629A
CN109475629A CN201780044786.9A CN201780044786A CN109475629A CN 109475629 A CN109475629 A CN 109475629A CN 201780044786 A CN201780044786 A CN 201780044786A CN 109475629 A CN109475629 A CN 109475629A
Authority
CN
China
Prior art keywords
cancer
monoclonal antibody
carcinoma
oxo
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780044786.9A
Other languages
English (en)
Chinese (zh)
Inventor
M.H.本德
高红
B.K.帕特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202211692364.1A priority Critical patent/CN115845070A/zh
Publication of CN109475629A publication Critical patent/CN109475629A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780044786.9A 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗 Pending CN109475629A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211692364.1A CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339363P 2016-05-20 2016-05-20
US62/339363 2016-05-20
PCT/US2017/032790 WO2017200969A1 (en) 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211692364.1A Division CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Publications (1)

Publication Number Publication Date
CN109475629A true CN109475629A (zh) 2019-03-15

Family

ID=58772978

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780044786.9A Pending CN109475629A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗
CN202211692364.1A Pending CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211692364.1A Pending CN115845070A (zh) 2016-05-20 2017-05-16 用notch和pd-1或pd-l1抑制剂的组合治疗

Country Status (15)

Country Link
US (2) US10688104B2 (enExample)
EP (1) EP3458091B1 (enExample)
JP (1) JP7194022B2 (enExample)
KR (1) KR102463617B1 (enExample)
CN (2) CN109475629A (enExample)
AU (1) AU2017268187A1 (enExample)
BR (1) BR112018073673A2 (enExample)
CA (1) CA3025024A1 (enExample)
ES (1) ES2904880T3 (enExample)
IL (1) IL263110B (enExample)
MA (1) MA45025A (enExample)
MX (1) MX2018013941A (enExample)
SG (1) SG11201810268YA (enExample)
WO (1) WO2017200969A1 (enExample)
ZA (1) ZA201807585B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
MX380780B (es) 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
JP2021506968A (ja) * 2017-12-18 2021-02-22 デビオファーム・インターナショナル・エス・アーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． 癌を治療するためのアゴニスト抗ＰＤ−１抗体とＧｎＲＨアゴニスト又はアンタゴニストとの併用
KR20220114532A (ko) * 2019-10-28 2022-08-17 주식회사 엔지켐생명과학 암의 치료를 위한 방법 및 조성물
EP4329745A4 (en) * 2021-04-28 2025-03-19 Obi Pharma, Inc. COMBINATION THERAPY USING AN AKR1C3-ACTIVATED COMPOUND WITH AN IMMUNE CHECKPOINT INHIBITOR
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073732A1 (en) * 2003-02-18 2004-09-02 Lorantis Limited Modulators of notch signalling and of immune cell costimulatory activity for immunotherapy
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
CN103732612A (zh) * 2011-07-27 2014-04-16 伊莱利利公司 Notch通路信号转导抑制剂化合物
JP2014525918A (ja) * 2011-08-01 2014-10-02 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
WO2015193352A1 (en) * 2014-06-17 2015-12-23 Medimmune Limited Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
WO2016040880A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
CN105451770A (zh) * 2013-08-20 2016-03-30 默沙东公司 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
WO2016070051A2 (en) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016069647A1 (en) * 2014-10-27 2016-05-06 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
WO2007004743A1 (en) 2005-07-05 2007-01-11 Fujifilm Corporation Copolymer and polymerizable composition
DE102006002966A1 (de) * 2006-01-21 2007-07-26 Schaeffler Kg Laufscheibe mit integrierter Wälzkörperlaufbahn
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
BRPI0815135A2 (pt) 2007-08-14 2015-02-03 Lilly Co Eli Derivados de azepina como inibidores de gama secretase.
KR20100101624A (ko) 2008-01-11 2010-09-17 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
US20120213029A1 (en) 2009-08-26 2012-08-23 Frxsh Ag Apparatus and method for mixing of a material to be mixed
WO2011060051A1 (en) 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CN102085372A (zh) 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
US9465158B2 (en) * 2014-09-04 2016-10-11 National Taiwan Normal University Light-guide coupler for modulating angular and spatial distributions of light source
CA2969877A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
SG10201913841SA (en) 2015-07-24 2020-03-30 Oncotracker Inc Gamma secretase modulators for the treatment of immune system dysfunction
MX380780B (es) 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN109562114A (zh) 2016-08-31 2019-04-02 伊莱利利公司 用于治疗实体瘤的给药方案
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073732A1 (en) * 2003-02-18 2004-09-02 Lorantis Limited Modulators of notch signalling and of immune cell costimulatory activity for immunotherapy
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
CN103732612A (zh) * 2011-07-27 2014-04-16 伊莱利利公司 Notch通路信号转导抑制剂化合物
JP2014525918A (ja) * 2011-08-01 2014-10-02 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
CN105451770A (zh) * 2013-08-20 2016-03-30 默沙东公司 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
WO2015193352A1 (en) * 2014-06-17 2015-12-23 Medimmune Limited Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
WO2016040880A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
WO2016069647A1 (en) * 2014-10-27 2016-05-06 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
WO2016070051A2 (en) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DREW M PARDOLL: "The blockade of immune checkpoints in cancer immunotherapy", 《NAT REV CANCER》 *
EVAN J LIPSON ET AL.: "Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody", 《CLIN CANCER RES》 *
JAMES F. SHANAHAN AND CHRISTIE NAGLIERI 主编: "《Manual of Pharmacology and Therapeutics》", 31 December 2008, THE MCGRAW-HILL COMPANIES *
JOAN MAUREL & ANTONIO POSTIGO: "Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice", 《CURR CANCER DRUG TARGETS》 *
MÉLISSA MATHIEU ET AL.: "Notch signaling regulates PD-1 expression during CD8(+) T-cell activation", 《IMMUNOL CELL BIOL》 *
周彬 等: "Notch-1阻断剂对骨肉瘤小鼠模型肿瘤生长的抑制作用及相关分子机制探究", 《海南医学院学报》 *
郑杰编著: "《肿瘤的细胞和分子生物学》", 30 January 2011, 上海科学技术出版社 *

Also Published As

Publication number Publication date
JP2019516733A (ja) 2019-06-20
ES2904880T3 (es) 2022-04-06
ZA201807585B (en) 2024-09-25
US20220008432A1 (en) 2022-01-13
EP3458091A1 (en) 2019-03-27
IL263110A (en) 2018-12-31
IL263110B (en) 2022-07-01
US10688104B2 (en) 2020-06-23
MX2018013941A (es) 2019-03-21
AU2017268187A1 (en) 2018-11-29
KR20190008913A (ko) 2019-01-25
US11826317B2 (en) 2023-11-28
JP7194022B2 (ja) 2022-12-21
KR102463617B1 (ko) 2022-11-03
EP3458091B1 (en) 2021-11-17
US20190192531A1 (en) 2019-06-27
CA3025024A1 (en) 2017-11-23
CN115845070A (zh) 2023-03-28
BR112018073673A2 (pt) 2019-02-26
WO2017200969A1 (en) 2017-11-23
MA45025A (fr) 2019-03-27
SG11201810268YA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
CN109475629A (zh) 用notch和pd-1或pd-l1抑制剂的组合治疗
Crinò et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
CN109310684A (zh) 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法
JP2019011376A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
Krueger et al. Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
CN109310685A (zh) 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法
Brown et al. Bortezomib, vorinostat, and dexamethasone combination therapy in relapsed myeloma: results of the phase 2 MUK four trial
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
JP7747307B2 (ja) 抗癌剤耐性の軽減、及び抗癌剤の感受性の増強のための医薬組成物及びその使用
CN106265660B (zh) A674563在携带flt3突变型基因的急性白血病中的用途
CN110494137A (zh) 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途
TW202241455A (zh) 使用akr1c3活化化合物與免疫檢查點抑制劑之組合療法
Mehta et al. Ps1073 preliminary results of astx660, a novel non-peptidomimetic ciap1/2 and xiap antagonist, in relapsed/refractory peripheral T-cell lymphoma and cutaneous T cell lymphoma
TW202421147A (zh) 用於治療套細胞淋巴瘤(MCL)之阿貝西尼(Abemaciclib)及維奈托克(Venetoclax)的組合
Nagata et al. A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia
WO2022105763A1 (zh) 靶向cd24的胃癌治疗方法
Xiao et al. DDDR-35. TARGETING GBM INVASION BY INHIBITING KCNA1 WITH 4-AMINOPYRIDINE: AN FDA APPROVED DRUG THAT EASILY PASS THROUGH THE BBB
Zhu et al. A New Hope: Clinical Advances in Targeted Therapies for Pediatric Diffuse Midline Glioma
Abueg et al. Biotherapies: Targeted Therapies and Immunotherapies
HK40004756B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK40004756A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
Huy et al. Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. Open Access Maced J Med Sci. 2019 Dec 30; 7 (24): 4244-4249
TW202139992A (zh) 用於癌症治療之醫藥組合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination